2 news · updated Jun 4, 2026

Gilead HIV shot rise

2026-06-03

From Academic Start-Up to Multibillion-Dollar Acquisition

Gilead Sciences completed a $3.15 billion acquisition of Tubulis, an academic start-up co-founded by Prof. Christian Hackenberger, to commercialize its antibody-drug conjugate technology.

cen · 2026-06-03 00:00 UTC

2026-05-05

Use of Gilead's HIV Prevention Shot Rises, But US Insurance Gaps Remain

Gilead Sciences' HIV prevention injection Yeztugo sees rising usage since launch, though insurance coverage gaps and high costs hinder widespread adoption compared to daily pills. Analysts project ann

reuters · 2026-05-05 03:01 UTC

Gilead HIV shot rise

From Academic Start-Up to Multibillion-Dollar Acquisition

Use of Gilead's HIV Prevention Shot Rises, But US Insurance Gaps Remain

Media coverage (2)

Related topics